Clinical Trial Update: Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 trial of nintedanib in patients with recurrent or persistent endometrial cancer; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-10-09